Tenapanor hydrochloride
CAS No. 1234365-97-9
Tenapanor hydrochloride ( AZD-1722 | RDX5791 )
产品货号. M10931 CAS No. 1234365-97-9
Tenapanor (AZD-1722;RDX5791) 是一种有效的选择性 Na+/H+ 交换器 3 (NHE3) 抑制剂,对人和大鼠 NHE3 的 IC50 分别为 5 和 10 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥2689 | 有现货 |
|
| 10MG | ¥4532 | 有现货 |
|
| 25MG | ¥9049 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tenapanor hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Tenapanor (AZD-1722;RDX5791) 是一种有效的选择性 Na+/H+ 交换器 3 (NHE3) 抑制剂,对人和大鼠 NHE3 的 IC50 分别为 5 和 10 nM。
-
产品描述Tenapanor (AZD-1722;RDX5791) is a potent, selective inhibitor of the Na+/H+ exchanger 3 (NHE3) with IC50 of 5 and 10 nM for human and rat NHE3, respectively; displays no inhibitory activities against . human intestinal transporters NHE1 (SLC9A1), NHE2 (SLC9A2), TGR5 (GPBAR1), ASBT and Pit-1; inhibits sodium uptake acted exclusively in the gastrointestinal tract in vivo, reduces extracellular fluid volume, left ventricular hypertrophy, albuminuria, and blood pressure in salt-fed nephrectomized rats, also reduces sodium and phosphorus absorption, protects against vascular calcification in rat model of CKD.Dyslipidemia Phase 3 Clinical.
-
体外实验——
-
体内实验Tenapanor hydrochloride (0.15, 0.5 mg/kg; p.o.) reduces passive paracellular phosphate absorption in rats.Tenapanor hydrochloride (0.15 mg/kg; p.o.; twice-daily for 11 consecutive days) increases the reduction in urinary phosphorus excretion in rats. Animal Model:Rats (intestinal loop model)Dosage:0.15, 0.5 mg/kgAdministration:P.o.Result:Reduced passive paracellular phosphate absorption by reduced urinary phosphate and sodium excretion after the high-phosphate meal and increased sodium and phosphate delivery to the cecum.Animal Model:8 weeks, 250 g male Sprague–Dawley ratsDosage:0.15 mg/kg in combination with sevelamer (0%, 0.75%, 1.5%, and 3% (wt/wt))Administration:Oral gavage; twice-daily for 11 consecutive daysResult:Significantly augmented the reduction in urinary phosphorus excretion.
-
同义词AZD-1722 | RDX5791
-
通路Membrane Transporter/Ion Channel
-
靶点Sodium Channel
-
受体Sodium Channel
-
研究领域Cardiovascular Disease
-
适应症Dyslipidemia
化学信息
-
CAS Number1234365-97-9
-
分子量1217.96
-
分子式C50H68Cl6N8O10S2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (82.10 mM)
-
SMILESCN1CC(C2=C(C1)C(=CC(=C2)Cl)Cl)C3=CC(=CC=C3)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C4=CC=CC(=C4)C5CN(CC6=C5C=C(C=C6Cl)Cl)C.Cl.Cl
-
化学全称3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide dihydrochloride
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
Anemoside B4
Anemomoside B4 抑制 IL-10 的分泌。
-
Butacaine
Butacaine 是一种可转逆的神经传导 (nerve conduction) 阻滞剂。
-
Silperisone HCl
Silperisone HCl (RGH-5002) blocks sodium and calcium channels in cells, decreases excitability and contractility of muscle cells, reduces peripheral tone, and acts as a muscle relaxant and peripheral vasodilator. Silperisone HCl is used to treat recurrent painful myoclonus due to spinal cord injury, abnormal hypertonia due to cerebrovascular disease, dystonia symptoms, cone tension syndrome, multiple sclerosis myospasm and myelitis. silperisone is a sodium channel protein type 2 alpha channel blocker. silperisone is an organosilicon similar to tolperisone, an organosilicon compound with centrally acting muscle relaxant properties.
021-51111890
购物车()
sales@molnova.cn

